Skip to content
10-Q

Quarterly Report

REGEN BIOPHARMA, INC. RGBP RGBPP

0001641172-25-011206

← back to feed
Filed
May 16, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 21.55M sh
Cash And Equivalents Q1 2025 · Dec 31, 2024 $135
Cash And Equivalents Q1 2025 · Sep 30, 2024 $716
Current Liabilities Q1 2025 · Dec 31, 2024 $5.87M
Current Liabilities Q1 2025 · Sep 30, 2024 $5.38M
Total Liabilities Q1 2025 · Dec 31, 2024 $5.87M
Total Liabilities Q1 2025 · Sep 30, 2024 $5.38M
Current Assets Q1 2025 · Dec 31, 2024 $173.68K
Current Assets Q1 2025 · Sep 30, 2024 $143.35K
Total Assets Q1 2025 · Dec 31, 2024 $191.42K
Total Assets Q1 2025 · Sep 30, 2024 $161.08K
Shares Diluted Q1 2025 · Dec 31, 2023 3.6M sh
Operating Cash Flow Q1 2025 · Dec 31, 2023 −$162.34K
Stockholders Equity restated Q1 2025 · Dec 31, 2023 −$5.24M
Stockholders Equity restated Q1 2025 · Sep 30, 2023 −$5.1M
Eps Diluted restated Q1 2025 · Dec 31, 2023 −$0.04
Eps Basic restated Q1 2025 · Dec 31, 2023 −$0.04
Rd Expense Q1 2025 · Dec 31, 2023 $47.53K
Net Income restated Q1 2025 · Dec 31, 2023 −$144.93K
Operating Income Q1 2025 · Dec 31, 2023 −$122.78K
Revenue Q1 2025 · Dec 31, 2023 $59.07K